Clinical Studies
HepAssure Inc. is the company behind PathFinder. We are dedicated to advancing liver health through innovative research and effective nutritional support. Our recent IRB-supervised pilot phase 2 clinical study explored the impact of a patented, specially formulated nutrient-repletion formula on patients with chronic liver disease, specifically focusing on liver fibrosis stages F3 and F4. The study, overseen by Principal Investigator Dr. Richard Melde, aimed to assess whether this patented formula could promote metabolic homeostasis and potentially reverse liver fibrosis through the repletion of depleted nutrients that are known to drive liver fibrosis.
During this ongoing research, patients with various forms of chronic liver disease participated, receiving a blend of Generally Regarded As Safe nutrients targeting disrupted metabolic pathways associated with liver conditions. While the study faced inherent limitations, including the absence of a control group, the results indicate encouraging improvements by fibroscan and lab blood tests in many participants, highlighting the potential of specialized nutrition in managing liver health. By addressing the unique metabolic needs and known nutritional deficiencies of patients with chronic liver disease, PathFinder’s patented nutritional repletion formula aims to foster better outcomes, and we are committed to pursuing further research to deepen our understanding and validate these findings. To learn more about the detailed results and implications of this study, we invite you to download the full PDF report and explore how nutritional support can play a crucial role in liver health management.
HepAssure Inc. is dedicated to finding funding for future randomized, placebo-controlled studies on this important nutritional management strategy.